French drugmaker Sanofi announced that it had secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies, Reuters reported.
In June, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of caplacizumab, which is prescribed to adults suffering from acquired thrombotic thrombocytopenic purpura (aTTP).
The US Food and Drug Administration (FDA), which has granted the drug and 'Fast Track' designation, is expected to follow suit in early 2019.
About 7,500 patients have acquired TTP symptoms across the United States, the European Union and Japan.
Sanofi hopes to launch caplacizumab in Germany later this year.
Caplacizumab was developed by Belgium company Ablynx, which was acquired by Sanofi earlier this year for 3.9 billion euros ($ 4.53 billion).